Comparative Pharmacology
Head-to-head clinical analysis: BRETHAIRE versus METAPROTERENOL SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRETHAIRE versus METAPROTERENOL SULFATE.
BRETHAIRE vs METAPROTERENOL SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Selective beta-2 adrenergic receptor agonist that activates adenylate cyclase, increasing intracellular cyclic AMP leading to bronchodilation and inhibition of mast cell mediator release.
2 inhalations (370 mcg each) by oral inhalation 4 times daily as needed; maximum 12 inhalations per day.
2.5 mg (0.25 mL of 1% solution) by nebulization every 6-8 hours. For oral, 20 mg every 6-8 hours.
None Documented
None Documented
3.8 hours (terminal elimination half-life; clinical context: dosing interval typically every 4-6 hours)
Terminal elimination half-life: 2-6 hours. Clinical context: Shorter half-life requires frequent dosing; prolongation in renal impairment.
Renal (25% unchanged, 75% as inactive sulfate conjugates), biliary/fecal (minimal)
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~40% as metabolites.
Category C
Category C
Beta-2 Adrenergic Agonist
Beta-2 Adrenergic Agonist